Published in Drug Week, November 11th, 2005
The placing has raised around US$21 million (GBP12 million) (before expenses) for the company, giving it a post-money market capitalization of over US$100 million (GBP58 million) at the placing price. Libertas Capital, who is currently establishing a presence in Hong Kong and China, is acting as nominated adviser and broker to BPL, which will be one of the first companies to have GDRs trading on AIM.
The company manufactures and sells generic pharmaceutical formulation products, active pharmaceutical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.